SCHEMBL2009960

SCHEMBL2009960

COc1cc(O)c2cnn(-c3ccc(OCc4ccccc4)c(F)c3)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.41
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 1/20 0.39
S1PR5 Q9H228 1/20 0.37
FFAR1 O14842 3/20 0.37
PPARD Q03181 2/20 0.37
MAPK14 Q16539 1/20 0.36
MAPT P10636 4/20 0.36
MAPK1 P28482 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NOD2 Q9HC29 1/20 0.36
CSF1R P07333 1/20 0.36
MAP4K1 Q92918 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
LRRK2 Q5S007 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2002493 0.90 MAPK14 (0.41) ERN1ALDH1A1HSD17B10S1PR5FFAR1
SCHEMBL2013480 0.89 MRGPRX4 (0.40) ERN1ALDH1A1S1PR5MAPK14MAPT
SCHEMBL2004763 0.89 S1PR5 (0.39) ERN1ALDH1A1S1PR5MAPK14MAPT
SCHEMBL2006708 0.87 MRGPRX4 (0.40) ERN1S1PR5MAPK14MAPTCDK1
SCHEMBL2003916 0.85 S1PR5 (0.40) ERN1ALDH1A1S1PR5FFAR1PPARD
SCHEMBL2006324 0.84 MAPT (0.37) ALDH1A1HSD17B10S1PR5MAPK14MAPT
SCHEMBL12572463 0.84 S1PR5 (0.36) ERN1ALDH1A1S1PR5MAPK14MAPT
SCHEMBL2002561 0.82 MAPK14 (0.41) ERN1ALDH1A1MAPK14CSF1RMAP4K1
SCHEMBL2009185 0.81 CYP11B1 (0.39) ALDH1A1HSD17B10MAPK1NPSR1LMNA
SCHEMBL2005842 0.81 ERN1 (0.41) ERN1S1PR5MAPK14MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
EP-2118068-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS Glaxo Group Limited (GB) 2009-11-18 EP disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GPER1, ESR2, ESRRB ERN1 1705/4885ALDH1A1 746/4885HSD17B10 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.